Paul Tudor Jones Protagonist Therapeutics, Inc Transaction History
Tudor Investment Corp Et Al
- $26.8 Billion
- Q3 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 13,858 shares of PTGX stock, worth $574,968. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,858Holding current value
$574,968% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding PTGX
# of Institutions
248Shares Held
56.7MCall Options Held
76.3KPut Options Held
114K-
Farallon Capital Management LLC San Francisco, CA5.86MShares$243 Million1.32% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$239 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$225 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$175 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$132 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.04B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...